Skip to main content
Research project

Novel Pharmaceutical Agents (XF-drugs) to Prevent and Proactively Manage Bacterial Biofilm and Fungal Infections in Dynamic Model Systems

Project overview

National Biofilms Innovation Centre (NBIC), UK. Proof of Concept (POC) Round 1 (Research Grant). £147,727 (£65,994.50 from NBIC, £81,732.50 from Destiny Pharma).
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.


Lead researcher

Professor Jeremy Webb

Professor of Microbiology
Other researchers

Professor Charles Keevil

Professor In Environmental Health Care

Professor Saul Faust MBBS, FRCPCH, PhD, FHEA, OBE

Professor Paediatric Immunology & Infect

Collaborating research institutes, centres and groups

to top